Nafziger A N, Schwartzman M S, Bertino J S
Research Institute Mary Imogene Bassett Hospital, Cooperstown, NY 13326.
J Clin Pharmacol. 1989 Aug;29(8):757-63. doi: 10.1002/j.1552-4604.1989.tb03413.x.
During the menstrual cycle, a 20% increase in creatinine clearance (CL(CR] has previously been reported between the menstrual (phase 1) and late luteal (phase 4) phases. Tobramycin pharmacokinetics and CL(CR) were studied in eight healthy women with documented, regular, ovulatory menses. During the first and fourth phases of the menstrual cycle (as determined by urinary luteinizing hormone peak and basal body temperature shift), subjects received tobramycin by intravenous bolus. Tobramycin half-life, total body clearance, and volume of distribution were not significantly different between the two study phases. No significant change in total urinary creatinine excretion or CL(CR) was seen between phases. Total 24 hour urinary recovery of tobramycin was 98-99.7%. We conclude that no significant changes in renal function, as evaluated by tobramycin pharmacokinetics and CL(CR), occur between these hormonally different phases of the menstrual cycle, and that urinary recovery of a single dose of tobramycin is nearly complete within 24 hours in premenopausal women with normal renal function.
此前有报道称，在月经周期中，月经（第1期）和黄体晚期（第4期）之间肌酐清除率（CL(CR)）会增加20%。对8名有记录的、月经周期规律且有排卵的健康女性的妥布霉素药代动力学和CL(CR)进行了研究。在月经周期的第1期和第4期（通过尿促黄体生成素峰值和基础体温变化确定），受试者接受静脉推注妥布霉素。两个研究阶段之间，妥布霉素的半衰期、全身清除率和分布容积无显著差异。各阶段之间，尿肌酐总排泄量或CL(CR)未见显著变化。妥布霉素24小时尿总回收率为98 - 99.7%。我们得出结论，在月经周期的这些激素不同阶段之间，通过妥布霉素药代动力学和CL(CR)评估的肾功能无显著变化，且肾功能正常的绝经前女性单次剂量的妥布霉素在24小时内尿回收率几乎是完全的。
